<DOC>
	<DOCNO>NCT01887678</DOCNO>
	<brief_summary>The aim study evaluate effectiveness safety combine Traumeel速 / Zeel速 injection placebo ( saline ) patient moderate-to-severe pain associate osteoarthritis knee .</brief_summary>
	<brief_title>Study Intra-articular Injections v Placebo Patients With Pain From Osteoarthritis Knee</brief_title>
	<detailed_description>The primary objective demonstrate superiority Traumeel速 Zeel速 co-administered intra-articular ( IA ) injection vs placebo IA injection change knee pain patient moderate severe knee pain associate osteoarthritis . The secondary objective evaluate reduction pain stiffness change physical function . Safety evaluate incidence treatment emergent adverse event treatment period follow period randomize patient .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Inclusion Criteria ( Screening Visit 1 ) : 1 . Osteoarthritis ( OA ) knee American College Rheumatology criterion 2 . Men woman 4580 year age . 3 . Have document diagnosis primary OA target knee base clinical radiographic criterion ( KellgrenLawrence Numerical Grading System Grade 23 ) tibialfemoral compartment target knee confirm standard postanterior weightbearing Xray knee full extension take &lt; /= 6 month prior Visit 1 . 4 . Currently take Nonsteroidal antiinflammatory drug ( NSAID ) , acetaminophen regular basis ( 47 days/ week ) last 2 week prior Visit 1 experience amelioration pain medication . 5 . Must 50foot walk test pain score le 40 mm 100 mm VAS target knee screen 6 . Pain nontarget ( contralateral ) knee must great 30 mm 100 mm VAS 50foot walk test , target knee must symptomatic . 7 . Willingness stop OA treatment . 8 . Fully informed risk enter study willing provide write consent enter study . 9 . Able understand willing comply study requirement , particularly weekly injection regimen administration study drug . 10 . Primary complaint pain immediately follow unassisted 50foot walk . They must show : 1. moderate severe pain score target knee demonstrate 40 90 mm record 100 mm VAS , 2 . 20 mm increase pain screen visit pain score ( `` flare '' ) 3. pain nontarget ( contralateral ) knee must &lt; /= 30 mm 100 mm VAS 1 . Known hypersensitivity allergy component Traumeel Zeel 2 . Known hypersensitivity allergy acetaminophen . 3 . Has body mass index ( BMI ) &gt; 38 kg/m2 . 4 . Avoidance , aversion , nonprescription medication . 5 . Clinical symptom meniscal instability significant valgus/ varus require corrective osteotomy 6 . Any major injury surgery target knee prior 12 month . 7 . One combination follow comorbidities : 1. inflammatory arthropathy , gout pseudogout within previous 6 month 2. avascular necrosis 3. severe bone joint deformity target knee 4. osteonecrosis either knee 5. fibromyalgia 6. pe anserine bursitis 7. lumbar radiculopathy refer pain either knee 8. neurogenic vascular claudication 9. significant anterior knee pain due diagnose isolated patellafemoral syndrome target knee 10. target knee joint infection skin disorder/infection area surround knee within previous 6 month 11. current treatment treatment cancer within previous 2 year ( exclude basal cell squamous cell carcinoma skin ) 8 . Participated experimental drug device study within prior one ( 1 ) month and/or IA injection six ( 6 ) month . 9 . Referred pain joint 10 . Significantly debilitate concurrent infection ( ) 11 . Significant ligamentous instability 12 . Any prior viscosupplementation therapy ( target knee ) within 6 month prior Screening 13 . Systemic IA injection corticosteroid joint within 3 month enrollment 14 . Therapy oral hyaluronic acid product , and/or oral pharmaceutical product contain glucosamine and/or chondroitin sulphate and/or diacerein 15 . Therapy opioids within last 90 day include intradermal delivery system ( patch ) 16 . Therapy autologous stem cell 17 . Therapy coumarins warfarin , Coumadin ; heparin derivative substance include low molecular weight heparin , synthetic pentasaccharide inhibitor factor Xa fondaparinux idraparinux ; direct factor Xa inhibitor rivaroxaban apixaban ; direct thrombin inhibitor hirudin , lepirudin , bivalirudin , argatroban dabigatran . 18 . Concomitant inflammatory rheumatologic , neurological cardiovascular disease could affect evaluation knee pain 19 . Ongoing litigation worker compensation musculoskeletal injury disorder 20 . Use alcohol 4 drink per day 21 . Clinically important axial deviation ( varus , valgus ) great 15 degree 22 . Concomitant severe OA hip joint , might interfere assessment require study 23 . Painful knee condition OA ( e.g. , Paget 's disease ) 24 . Hemiparesis low limb 25 . Significant plan surgery lower limb , might interfere patient 's ability comply study requirement 26 . Presence serious gastrointestinal , renal , hepatic , pulmonary , cardiovascular , neurological disease might interfere outcome study patient 's ability comply study requirement 27 . Presence infection and/or skin disease area injection site psoriasis 28 . Females pregnant breastfeed use recognize effective contraceptive measure . Females childbearing potential ( include less one year postmenopausal ) must agree maintain reliable birth control throughout study . 29 . Clinically significant abnormal laboratory value . 30 . Patients likely noncompliant uncooperative study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>